Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIB Grifols in Congenital Afibrinogenemia
NCT02281500Phase 2Completed
- Sponsor
- Grifols
- Start
- Jul 2016
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of Fibrinogen human in congenital afibrinogenemia, sponsored by Grifols. Primary endpoints: Area Under the Plasma Fibrinogen Concentration-time Curve From Time Zero to 14 Days, Area Under the Plasma Fibrinogen Concentration-time Curve From Time Zero to Infinite Time and 8 more. Started Jul 2016; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
congenital afibrinogenemia
Beyond the preview
Go deeper on NCT02281500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281500.